Hong Kong, China; Research Site:
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Metastatic Nasopharyngeal Cancer
Jogjakarta, Indonesia; Research Site:
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Metastatic Nasopharyngeal Cancer
Kuala Lumpur, Malaysia; Research Site:
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Metastatic Nasopharyngeal Cancer
Casablanca, Morocco; Research Site:
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Marrakech, Morocco; Research Site:
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Rabat, Morocco; Research Site:
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Kueishan, Taiwan; Research Site:
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Metastatic Nasopharyngeal Cancer
Taipei, Taiwan; Research Site:
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Metastatic Nasopharyngeal Cancer
Bangkok, Thailand; Research Site:
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Metastatic Nasopharyngeal Cancer
